Get the Stockscreener App
13.06
0.15%
-0.02
After Hours:
13.05
-0.010
-0.08%
Crescent Biopharma Inc stock is traded at $13.06, with a volume of 24,799.
It is down -0.15% in the last 24 hours and up +3.24% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$13.08
Open:
$13.25
24h Volume:
24,799
Relative Volume:
0.24
Market Cap:
$181.44M
Revenue:
$6.67M
Net Income/Loss:
$-47.55M
P/E Ratio:
-8.7067
EPS:
-1.5
Net Cash Flow:
$-17.44M
1W Performance:
+0.31%
1M Performance:
+3.24%
6M Performance:
+2,454%
1Y Performance:
+2,454%
1-Day Range:
$12.84
$13.27
1-Week Range:
$12.76
$13.50
52-Week Range:
$9.81
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
13.06 | 219.52M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Is Crescent Biopharma Inc. (GKO0) stock protected from inflationJuly 2025 Institutional & Weekly Top Performers Watchlists - newser.com
Will Crescent Biopharma Inc. (GKO0) stock recover faster than industryJuly 2025 Opening Moves & Safe Entry Point Alerts - newser.com
Is Crescent Biopharma Inc. (GKO0) stock a top hedge fund pickExit Point & AI Powered Buy/Sell Recommendations - newser.com
What valuation ratios show for Crescent Biopharma Inc. (GKO0) stock2025 Top Decliners & Daily Entry Point Alerts - newser.com
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Average Recommendation of “Buy” from Analysts - Defense World
Crescent Biopharma (Nasdaq: CBIO) Approves 451,448-Share Inducement Options at $13.02 - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Upgraded by Wall Street Zen to Hold Rating - Defense World
Is Crescent Biopharma Inc. (GKO0) stock expanding market penetrationEntry Point & Long-Term Safe Return Strategies - newser.com
What market sentiment indicators show for Crescent Biopharma Inc. (GKO0) stock2025 Price Targets & Community Consensus Picks - newser.com
Can Crescent Biopharma Inc. (GKO0) stock beat analyst consensusBond Market & AI Forecasted Entry and Exit Points - newser.com
Will Crescent Biopharma Inc. (GKO0) stock top growth indexes2025 Volume Leaders & Advanced Swing Trade Entry Alerts - newser.com
Crescent Biopharma to present preclinical data from CR-001 - MSN
Crescent Biopharma, Inc. (C68.F) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
Crescent Biopharma Advances Cancer Therapy Pipeline - MSN
Crescent Biopharma, Inc. (C68.F) Interactive Stock Chart - Yahoo! Finance Canada
Crescent Biopharma: Q3 Earnings Snapshot - theheraldreview.com
Crescent Biopharma, Inc. (C68.F) Analyst Ratings, Estimates & Forecasts - Yahoo! Finance Canada
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
[S-8] CRESCENT BIOPHARMA, INC. Employee Benefit Plan Registration | CBIO SEC FilingForm S-8 - Stock Titan
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView
Crescent Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[8-K] CRESCENT BIOPHARMA, INC. Reports Material Event | CBIO SEC FilingForm 8-K - Stock Titan
Crescent Biopharma to Present at November Investor Conferences - The Manila Times
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):